Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Nazanin Tatari Clear advanced filters

  • Although it has shown high efficacy in many tumor types, interleukin-12 (IL-12) treatment provokes severe systemic toxicity. Here, the authors discover that use of an IL-12Fc fusion cytokine with abolished binding to the neonatal Fc receptor presents efficacy in local glioblastoma therapy while preventing toxicity.

    • Michal Beffinger
    • Linda Schellhammer
    • Johannes vom Berg
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-19

  • EGFRvIII-targeted CAR T cells have been proposed as a therapeutic option for patients with glioblastoma (GBM), however, clinical responses remain suboptimal. Here the authors engineer anti-EGFRvIII CAR T cells to secrete an optimized SIRPγ-derived CD47 blocker, showing that combining CAR T cell effector functions with enhanced macrophage-mediated tumor cell phagocytosis improves anti-tumor efficacy in preclinical models.

    • Tomás A. Martins
    • Deniz Kaymak
    • Gregor Hutter
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-25

  • Functional CRISPR screens in patient-matched pre-treatment and post-treatment glioblastoma models identify the PTP4A–ROBO1 axis as a driver of tumorigenicity and enriched ROBO1 expression in recurrent glioblastoma that can be targeted with CAR T cell therapy.

    • Chirayu R. Chokshi
    • Muhammad Vaseem Shaikh
    • Sheila K. Singh
    Research
    Nature Medicine
    Volume: 30, P: 2936-2946

  • The Wnt molecular subgroup of medulloblastoma is associated with better prognosis than the other molecular subgroups. Here, the authors show that activating Wnt signaling impairs tumor development and improves survival in Group 3 and Group 4 medulloblastoma preclinical models.

    • Branavan Manoranjan
    • Chitra Venugopal
    • Sheila K. Singh
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-12